Postmenopausal estrogen and estrogen-progestin use and 2-year rate of cognitive change in a cohort of older Japanese American women: The kame project

Archives of Internal Medicine

Volumn 160, Issue 11, 2000, Pages 1641-1649

  Rice, Madeline Murguia ^a   Graves, Amy Borenstein ^b   McCurry, Susan M ^a   Gibbons, Laura E ^a   Bowen, Jim D ^a   McCormick, Wayne C ^a   Larson, Eric B ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN;

AGED; ARTICLE; COGNITION; DISEASE ASSOCIATION; ESTROGEN BLOOD LEVEL; FEMALE; HORMONAL THERAPY; HUMAN; HUMAN CELL; HUMAN TISSUE; JAPAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PREVALENCE; PRIORITY JOURNAL;

EID: 0034640780     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.160.11.1641     Document Type: Article

References (77)

1. Tang M-X, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet. 1996;348:429-432.
2. Kawas C, Resnick S, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology. 1997;48:1517-1521.
3. Baldereschi M, Di Carlo A, Lepore V, et al. Estrogen-replacement therapy and Alzheimer's disease in the Italian Longitudinal Study on Aging. Neurology. 1998; 50:995-1002.
4. Henderson VW, Paganini-Hill A, Emanuel CK, Dunn ME, Buckwalter JG. Estrogen replacement therapy in older women: comparisons between Alzheimer's disease cases and nondemented control subjects. Arch Neurol. 1994;51:896-900.
5. Paganini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol. 1994;140:256-261.
6. Heyman A, Wilkinson WE, Stafford JA, Helms MJ, Sigmon AH, Weinberg T. Alzheimer's disease: a study of epidemiological aspects. Ann Neurol. 1984, 15: 335-341.
7. Amaducci LA, Fratiglioni L, Rocca WA, et al. Risk factors for clinically diagnosed Alzheimer's disease: a case-control study of an Italian population. Neurology. 1986;36:922-931.
8. Broe GA, Henderson AS, Creasey H, et al. A case-control study of Alzheimer's disease in Australia. Neurology. 1990;40:1698-1707.
9. Graves AB, White E, Koepsell TD, et al. A case-control study of Alzheimer's disease. Ann Neurol. 1990;28:766-774.
10. Brenner DE, Kukull WA, Stergachis A, et al. Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease: a population-based case-control study. Am J Epidemiol. 1994;140:262-267.
11. Mortel KF, Meyer JS. Lack of postmenopausal estrogen replacement therapy and the risk of dementia. J Neuropsychiatry Clin Neurosci. 1995;7:334-337.
12. Fillit H, Weinreb H, Cholst I, et al. Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type. Psychoneuroendocrinology. 1986;11:337-345.
13. Honjo H, Ogino Y, Naitoh K, et al. In vivo effects by estrone sulfate on the central nervous system-senile dementia (Alzheimer's type). J Steroid Biochem. 1989; 34:521-525.
14. Ohkura T, Isse K, Akazawa K, Hamamoto M, Yaoi Y, Hagino N. Evaluation of estrogen treatment infernale patients with dementia of the Alzheimer type. Endocr J. 1994; 41:361-371.
15. Honjo H, Ogino K, Tanaka M, et al. An effect of conjugated estrogen to cognitive impairment in women with senile dementia-Alzheimer's type: a placebo-controlled double blind study. J Jpn Menopause Soc. 1993;1:167-171.
16. Caldwell BM, Watson RI. An evaluation of psychologic effects of sex hormone administration in aged women: I, results of therapy after six months. J Gerontol. 1952;7:228-244.
17. Rauramo L, Lagerspetz K, Engblom P, Punnonen R. The effect of castration and peroral estrogen therapy on some psychological functions. Front Horm Res. 1975; 3:94-104.
18. Vanhulle G, Demol R. A double-blind study into the influence of estriol on a number of psychological tests in post-menopausal women. In: van Keep PA, Greenblatt RB, Albeaux-Fernet M, eds. Consensus on Menopause Research: A Summary of International Opinion. Baltimore, Md: University Park Press; 1976: 94-99.
19. Fedor-Freybergh P. The influence of oestrogens on the wellbeing and mental performance in climacteric and postmenopausal women. Acta Obstet Gynecol Scand Suppl. 1977;64:1-91.
20. Sherwin BB. Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. Psychoneuroendocrinology. 1988;13: 345-357.
21. Sherwin BB, Phillips S. Estrogen and cognitive functioning in surgically menopausal women. Ann N Y Acad Sci. 1990;592:474-475.
22. Ditkoff EC, Crary WG, Cristo M, Lobo RA. Estrogen improves psychological function in asymptomatic postmenopausal women. Obstet Gynecol. 1991;78: 991-995.
23. Phillips SM, Sherwin BB. Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology. 1992;17:485-495.
24. Barrett-Connor E, Kritz-Silverstein D. Estrogen replacement therapy and cognitive function in older women. JAMA. 1993;269:2637-2641.
25. Kampen DL, Sherwin BB. Estrogen use and verbal memory in healthy postmenopausal women. Obstet Gynecol. 1994;83:979-983.
26. Robinson D, Friedman L, Marcus R, Tinklenberg J, Yesavage J. Estrogen replacement therapy and memory in older women. J Am Geriatr Soc. 1994;42: 919-922.
27. Kimura D. Estrogen replacement therapy may protect against intellectual decline in postmenopausal women. Horm Behav. 1995;29:312-321.
28. Schmidt R, Fazekas F, Reinhart B, et al. Estrogen replacement therapy in older women: a neuropsychological and brain MRI study. J Am Geriatr Soc. 1996;44: 1307-1313.
29. Szklo M, Cerhan J, Diez-Roux AV, et al. Estrogen replacement therapy and cognitive functioning in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol. 1996;144:1048-1057.
30. Resnick SM, Metter EJ, Zonderman AB. Estrogen replacement therapy and longitudinal decline in visual memory: a possible protective effect? Neurology. 1997; 49:1491-1497.
31. Jacobs DM, Tang MX, Stern Y, et al. Cognitive function in nondemented older women who took estrogen after menopause. Neurology. 1998;50:368-373.
32. Polo-Kantola P, Portin R, Polo O, Helenius H, Irjala K, Erkkola R. The effect of short-term estrogen replacement therapy on cognition: a randomized, double-blind, cross-over trial in postmenopausal women. Obstet Gynecol. 1998;91:459-466.
33. Matsumoto A, Arai Y, Osanai M. Estrogen stimulates neuronal plasticity in the deafferented hypothalamic arcuate nucleus in aged female rats. Neurosci Res. 1985;2:412-418.
34. Gould E, Woolley CS, Frankfurt M, McEwen BS. Gonadal steroids regulate dendritic spine density in hippocampal pyramidal cells in adulthood. J Neurosci. 1990; 10:1286-1291.
35. Woolley CS, Gould E, Frankfurt M, McEwen BS. Naturally occurring fluctuation in dendritic spine density on adult hippocampal pyramidal neurons. J Neurosci. 1990;10:4035-4039.
36. Woolley CS, McEwen BS. Roles of estradiol and progesterone in regulation of hippocampal dendritic spine density during the estrous cycle in the rat. J Comp Neurol. 1993;336:293-306.
37. McEwen BS, Woolley CS. Estradiol and progesterone regulate neuronal structure and synaptic connectivity in adult as well as developing brain. Exp Gerontol. 1994;29:431-436.
38. Woolley CS, McEwen BS. Estradiol regulates hippocampal dendritic spine density via an N-methyl-D-aspartate receptor-dependent mechanism. J Neurosci. 1994;14:7680-7687.
39. Brinton RD, Tran J, Proffitt P, Montoya M. 17 β-Estradiol enhances the outgrowth and survival of neocortical neurons in culture. Neurochem Res. 1997; 22:1339-1351.
40. Toran-Allerand CD, Miranda RC, Bentham WDL, et al. Estrogen receptors colocalize with low-affinity nerve growth factor receptors in cholinergic neurons of the basalforebrain. Proc Natl Acad Sci U S A. 1992;89:4668-4672.
41. Singh M, Meyer EM, Simpkins JW. The effect of ovariectomy and estradiol replacement on brain-derived neurotrophic factor messenger ribonucleic acid expression in cortical and hippocampal brain regions of female Sprague-Dawley rats. Endocrinology. 1995;136:2320-2324.
42. Luine V, Park D, Joh T, Reis D, McEwen B. Immunochemical demonstration of increased choline acetyltransferase concentration in rat preoptic area after estradioladministration. Brain Res. 1980;191:273-277.
43. Luine VN. Estradiol increases choline acetyltransferase activity in specific basal forebrain nuclei and projection areas of female rats. Exp Neurol. 1985;89:484-490.
44. Behl C, Widmann M, Trapp T, Holsboer F. 17-β Estradiol protects neurons from oxidative stress-induced cell death in vitro. Biochem Biophys Res Commun. 1995; 216:473-482.
45. Green PS, Gridley KE, Simpkins JW. Estradiol protects against β-amyloid (25-35)-induced toxicity in SK-N-SH human neuroblastoma cells. Neurosci Lett. 1996; 218:165-168.
46. Singer CA, Rogers KL, Strickland TM, Dorsa DM. Estrogen protects primary cortical neurons from glutamate toxicity. Neurosci Lett. 1996;212:13-16.
47. Penotti M, Nencioni T, Gabrielli L, Farina M, Castiglioni E, Polvani F. Blood flow variations in internal carotid and middle cerebral arteries induced by postmenopausal hormone replacement therapy. Am J Obstet Gynecol. 1993;169:1226-1232.
48. Ohkura T, Teshima Y, Isse K, et al. Estrogen increases cerebral and cerebellar blood flows in postmenopausal women. Menopause. 1995;2:13-18.
49. Holzbauer M, Youdim MB. The oestrous cycle and monoamine oxidase activity. Br J Pharmacol. 1973;48:600-608.
50. Luine VN, Khylchevskaya RI, McEwen BS. Effect of gonadal steroids on activities of monoamine oxidase and choline acetylase in rat brain. Brain Res. 1975; 86:293-306.
51. Luine VN, McEwen BS. Effect of oestradiol on turnover of type A monoamine oxidase in brain. J Neurochem. 1977;28:1221-1227.
52. Graves AB, Larson EB, Edland SD, et al. Prevalence of dementia and its subtypes in the Japanese American population of King County, Washington state: the Kame Project. Am J Epidemiol. 1996;144:760-771.
53. Radloff LS. The CES-D scale: a self report depression scale for research in the general population. Appl Psychol Meas. 1977;3:385-401.
54. Kohout FJ, Berkman LF, Evans DA, Cornoni-Huntley J. Two shorter forms of the CES-D (Center for Epidemiological Studies Depression) depression symptoms index. J Aging Health. 1993;5:179-193.
55. Teng EL, Hasegawa K, Homma A, et al. The Cognitive Abilities Screening Instrument (CASI): a practical test for cross-cultural epidemiological studies of dementia. Int Psychogeriatr. 1994;6:45-58.
56. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12:189-198.
57. Hasegawa K. The clinical assessment of dementia in the aged: a dementia screening scale for psychogeriatrics patients. In: Bergener M, Lehr U, Lang E, Schmitz-Scherzer R, eds. Aging in the Eighties and Beyond: Highlights of the Twelfth International Congress of Gerontology. New York, NY: Springer Publishing Co; 1983; 207-218.
58. Teng EL, Chui HC. The modified Mini-Mental State (3MS) Examination. J Clin Psychiatry. 1987;48:314-318.
59. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition. Washington, DC: American Psychiatric Association; 1987.
60. Graves AB, Larson EB, Kukull WA, White LR, Teng EL. Screening for dementia in the community in cross-national studies: comparison between the Cognitive Abilities Screening Instrument and the Mini-Mental State Examination. In: Corain B, Iqbal K, Nicolini M, Winblad B, Wisniewski H, Zatta P, eds. Alzheimer's Disease: Advances in Clinical and Basic Research. New York, NY: John Wiley & Sons Inc; 1993:113-119.
61. Sherwin BB. Estrogenic effects on memory in women. Ann N Y Acad Sci. 1994; 743:213-231.
62. Rice MM, Graves AB, McCurry SM, Larson EB. Estrogen replacement therapy and cognitive function in postmenopausal women without dementia. Am J Med. 1997;103:26S-35S.
63. Paganini-Hill A, Henderson VW. The effects of hormone replacement therapy, lipoprotein cholesterol levels, and other factors on a clock drawing task in older women. J Am Geriatr Soc. 1996;44:818-822.
64. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA. 1995;273:199-208.
65. Barrett-Connor E, Slone S, Greendale G, et al. The Postmenopausal Estrogen/ Progestin Interventions Study: primary outcomes in adherent women. Maturitas. 1997;27:261-274.
66. Gelfand MM, Fugere P, Bissonnette F, et al. Conjugated estrogens combined with sequential dydrogesterone or medroxyprogesterone acetate in postmenopausal women: effects on lipoproteins, glucose tolerance, endometrial histology, and bleeding. Menopause. 1997;4:10-18.
67. Kim CJ, Min YK, Ryu WS, Kwak JW, Ryoo UH. Effect of hormone replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women: influence of various progestogens and duration of therapy. Arch Intern Med. 1996;156: 1693-1700.
68. Kuusisto J, Koivisto K, Mykkänen L, et al. Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipo-protein E4 phenotype: cross sectional population based study. BMJ. 1997;315: 1045-1049.
69. Gerdes LC, Sonnendecker EW, Polakow ES. Psychological changes effected by estrogen-progestogen and clonidine treatment in climacteric women. Am J Obstet Gynecol. 1982;142:98-104.
70. Sherwin BB, Gelfand MM. A prospective one-year study of estrogen and progestin in postmenopausal women: effects on clinical symptoms and lipoprotein lipids. Obstet Gynecol. 1989;73:759-766.
71. Palinkas LA, Barrett-Connor E. Estrogen use and depressive symptoms in postmenopausal women. Obstet Gynecol. 1992;80:30-36.
72. Limouzin-Lamothe MA, Marion N, Joyce CR, Le Gal M. Quality of life after the menopause: influence of hormonal replacement therapy. Am J Obstet Gynecol. 1994;170:618-624.
73. Dennerstein L, Burrows GD, Hyman GJ, Sharpe K. Hormone therapy and affect. Maturitas. 1979;1:247-259.
74. Magos AL, Brewster E, Singh R, O'Dowd T, Brincat M, Studd JW. The effects of norethisterone in postmenopausal women on oestrogen replacement therapy: a model for the premenstrual syndrome. Br J Obstet Gynaecol. 1986;93:1290-1296.
75. Holst J, Bäckström T, Hammarbäck S, von Schoultz B. Progestogen addition during oestrogen replacement therapy: effects on vasomotor symptoms and mood. Maturitas. 1989;11:13-20.
76. Sherwin BB. The impact of different doses of estrogen and progestin on mood and sexual behavior in postmenopausal women. J Clin Endocrinol Metab. 1991; 72:336-343.
77. Frank R, Wiederholt WC, Kritz-Silverstein D, Salmon DP, Barrett-Connor E. Effects of sequential neuropsychological testing of an elderly community-based sample. Neuroepidemiology. 1996;15:257-268.